Inspire Investing LLC Has $352,000 Position in ICU Medical, Inc. (NASDAQ:ICUI)

Inspire Investing LLC decreased its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 11.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,966 shares of the medical instruments supplier’s stock after selling 386 shares during the period. Inspire Investing LLC’s holdings in ICU Medical were worth $352,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in ICUI. Motco acquired a new stake in shares of ICU Medical in the 1st quarter valued at $29,000. Innealta Capital LLC bought a new stake in shares of ICU Medical during the 2nd quarter worth $32,000. GAMMA Investing LLC boosted its stake in ICU Medical by 75.1% in the first quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 133 shares in the last quarter. EntryPoint Capital LLC grew its position in ICU Medical by 731.5% in the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock valued at $48,000 after acquiring an additional 395 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its stake in ICU Medical by 681.6% during the fourth quarter. Quadrant Capital Group LLC now owns 594 shares of the medical instruments supplier’s stock worth $59,000 after acquiring an additional 518 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. KeyCorp raised their target price on shares of ICU Medical from $136.00 to $147.00 and gave the company an “overweight” rating in a research report on Thursday, August 8th. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a report on Thursday, August 8th. Finally, Raymond James raised their price objective on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $149.00.

Insider Buying and Selling

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,050 shares of the stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $144.11, for a total transaction of $295,425.50. Following the completion of the sale, the vice president now owns 4,482 shares of the company’s stock, valued at approximately $645,901.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,050 shares of the company’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $144.11, for a total transaction of $295,425.50. Following the sale, the vice president now owns 4,482 shares of the company’s stock, valued at $645,901.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $163.46, for a total value of $1,961,520.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $17,096,771.78. The disclosure for this sale can be found here. Insiders have sold a total of 28,552 shares of company stock valued at $4,537,802 over the last ninety days. 6.70% of the stock is owned by company insiders.

ICU Medical Trading Down 2.5 %

Shares of NASDAQ ICUI opened at $176.74 on Monday. The firm has a 50 day moving average price of $149.89 and a two-hundred day moving average price of $121.63. The stock has a market cap of $4.31 billion, a P/E ratio of -72.14 and a beta of 0.65. ICU Medical, Inc. has a 52-week low of $78.28 and a 52-week high of $181.87. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.56. The business had revenue of $596.50 million during the quarter, compared to the consensus estimate of $556.64 million. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. ICU Medical’s quarterly revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.58 earnings per share. As a group, equities analysts forecast that ICU Medical, Inc. will post 3.76 EPS for the current year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.